Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy
Autor: | Valeria, Ricotti, Deborah A, Ridout, Elaine, Scott, Ros, Quinlivan, Stephanie A, Robb, Adnan Y, Manzur, Francesco, Muntoni, E, Scott |
---|---|
Rok vydání: | 2012 |
Předmět: |
Male
Pediatrics medicine.medical_specialty Neuromuscular disease Adolescent Duchenne muscular dystrophy Prednisolone Drug Administration Schedule law.invention Randomized controlled trial law Medicine Humans Prospective Studies Adverse effect Child Glucocorticoids business.industry medicine.disease Muscular Dystrophy Duchenne Psychiatry and Mental health Regimen Treatment Outcome Child Preschool Ambulatory Physical therapy Surgery Neurology (clinical) business Body mass index medicine.drug |
Zdroj: | Journal of neurology, neurosurgery, and psychiatry. 84(6) |
ISSN: | 1468-330X |
Popis: | OBJECTIVE To assess the current use of glucocorticoids (GCs) in Duchenne muscular dystrophy in the UK, and compare the benefits and the adverse events of daily versus intermittent prednisolone regimens. DESIGN A prospective longitudinal observational study across 17 neuromuscular centres in the UK of 360 boys aged 3-15 years with confirmed Duchenne muscular dystrophy who were treated with daily or intermittent (10 days on/10 days off) prednisolone for a mean duration of treatment of 4 years. RESULTS The median loss of ambulation was 12 years in intermittent and 14.5 years in daily treatment; the HR for intermittent treatment was 1.57 (95% CI 0.87 to 2.82). A fitted multilevel model comparing the intermittent and daily regiments for the NorthStar Ambulatory Assessment demonstrated a divergence after 7 years of age, with boys on an intermittent regimen declining faster (p |
Databáze: | OpenAIRE |
Externí odkaz: |